Furthermore, UGDH blockade using genetic approaches (sgUGDH) or pharmacological inhibitors (4‐MU) inhibited tumour cell migration, whereas supplementing UDP‐GlcUA fully restored the migratory capacity of UGDH‐depleted hepatoma cells (Figure S3F,I and Figure S3J–M), suggesting that accumulating the key intermediate metabolite UDP‐GlcUA, due to UGDH upregulation, may be critical for the pro‐metastatic phenotype mediated by GSTZ1 deficiency. Here, GSTZ1 is linked to hepatocellular carcinoma.